Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182701 | 0.84 | PARL (0.39) | PARLALOX12 | |
| SCHEMBL7139394 | 0.84 | MGLL (0.42) | GSK3AGSK3BMGLL | |
| SCHEMBL19928412 | 0.73 | MGLL (0.35) | PARLMGLL | |
| SCHEMBL18522835 | 0.70 | ALOX12 (0.41) | PARLALOX12GSK3AGSK3BMGLL | |
| SCHEMBL5669050 | 0.67 | MGLL (0.43) | PARLMGLL | |
| SCHEMBL4955196 | 0.67 | PARL (0.33) | PARL | |
| SCHEMBL18122756 | 0.66 | SMN1; SMN2 (0.38) | ALOX12GSK3AGSK3BMGLL | |
| SCHEMBL6241665 | 0.66 | GSK3A (0.30) | GSK3AGSK3BMGLL | |
| SCHEMBL4882564 | 0.66 | MGLL (0.53) | ALOX12GSK3AGSK3BMGLL | |
| SCHEMBL10666060 | 0.66 | MGLL (0.42) | GSK3AGSK3BMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207435-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3187557-B1 | ADHESIVE FILM AND SEMICONDUCTOR PACKAGE USING ADHESIVE FILM | FURUKAWA ELECTRIC CO LTD (JP) | 2023-09-13 | — | — | EP | disclosed |
| EP-3958977-B1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11730822-B2 | Process for the preparation of glucuronide drug-linkers and intermediates thereof | SEAGEN INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11547762-B2 | Methods for preparing antibody drug conjugates | GENENTECH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| WO-2021209007-A1 | ANTIBODY-DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2021-10-21 | — | — | WO | disclosed |
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-08-27 | — | — | US | disclosed |
| US-20200222553-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | SEATTLE GENETICS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-04-28 | — | — | US | disclosed |
| EP-3003386-B1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2019-10-16 | — | — | EP | disclosed |
| US-20190201544-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| EP-2928503-B1 | CONJUGATES OF AURISTATIN COMPOUNDS | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017172930-A1 | PBD CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730822-B2 | Process for the preparation of glucuronide drug-linkers and intermediates thereof | UGT1A4, UGT1A1, UGT2B7 | PARL 4724/4885ALOX12 2632/4885GSK3A 1725/4885 |
| US-20240207435-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | UGT1A4, UGT1A1, UGT2B7 | PARL 4724/4885ALOX12 2632/4885GSK3A 1725/4885 |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | PARL 4320/4885ALOX12 1957/4885GSK3A 1392/4885 |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | PARL 4718/4885ALOX12 3308/4885GSK3A 1884/4885 |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | PARL 3787/4885ALOX12 3283/4885GSK3A 3030/4885 |
| US-11547762-B2 | Methods for preparing antibody drug conjugates | FCGRT, MSN, FCGR3B | PARL 3787/4885ALOX12 3283/4885GSK3A 3030/4885 |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | PARL 4718/4885ALOX12 3308/4885GSK3A 1884/4885 |
| US-20190201544-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | PARL 3787/4885ALOX12 3283/4885GSK3A 3030/4885 |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | PARL 2608/4885ALOX12 4587/4885GSK3A 4548/4885 |
| US-20200222553-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | UGT1A4, UGT1A1, UGT2B7 | PARL 4724/4885ALOX12 2632/4885GSK3A 1725/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | PARL 4113/4885ALOX12 4539/4885GSK3A 3785/4885 |
| US-11046762-B2 | Cross-linkers and their uses | MTCL3, DCLRE1A, PCNA | PARL 2608/4885ALOX12 4587/4885GSK3A 4548/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | PARL 4320/4885ALOX12 1957/4885GSK3A 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.